TRIAL IN PROGRESS: THE FIRST 12-WEEK, RANDOMIZED, CONTROLLED PHASE 2a STUDY OF A THYROID HORMONE RECEPTOR-.ETA AGONIST (TERN-501) ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH A FARNESOID X RECEPTOR AGONIST ( TERN--101) IN PATIENTS WITH NASH